Seelos Therapeutics 1-for-30 reverse split; authorized shares cut to 16M

SEELOS THERAPEUTICS, INC.

1-for-30 reverse stock split effective Nov 28, 2023; fractional shares rounded up.
Authorized common shares reduced from 480M to 16M.
Reverse split intended to regain Nasdaq $1.00 minimum bid compliance.
Trading symbol remains 'SEEL'; new CUSIP 81577F208.
Proportionate adjustments to warrants, options, and equity plan exercise prices.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

SEELOS THERAPEUTICS, INC.: Filed a Certificate of Change with Nevada Secretary of State to effect a 1-for-30 reverse stock split and decrease authorized common shares from 480,000,000 to 16,000,000 (effective 2023-11-28).

Change: charter amendment
Effective: 2023-11-28

Exact text from the filing

On November 27, 2023, Seelos Therapeutics, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to (i) effect a 1-for-30 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), and (ii) decrease the number of total authorized shares of Common Stock from 480,000,000 shares to 16,000,000 shares.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001104659-23-121463

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.